MARKET

DSGN

DSGN

Design Therapeutics, Inc.
NASDAQ
10.80
+0.59
+5.78%
After Hours: 10.80 0 0.00% 16:10 11/09 EST
OPEN
10.36
PREV CLOSE
10.21
HIGH
10.83
LOW
10.10
VOLUME
375.65K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
6.16
MARKET CAP
691.59M
P/E (TTM)
-9.1487
1D
5D
1M
3M
1Y
5Y
1D
Design Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 4d ago
Design Therapeutics Price Target Cut to $19.00/Share From $20.00 by RBC Capital
Dow Jones · 4d ago
RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19
Benzinga · 4d ago
RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)
TipRanks · 4d ago
Leerink Partners Sticks to Their Buy Rating for Design Therapeutics (DSGN)
TipRanks · 4d ago
Design Therapeutics GAAP EPS of -$0.32 beats by $0.02
Seeking Alpha · 4d ago
Design Therapeutics Authorizes Up To $200M In Common Stock Sales Through Jefferies
Benzinga · 4d ago
Design Therapeutics Files Prospectus For Offering $300M Mixed Shelf
Benzinga · 4d ago
More
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Webull offers Design Therapeutics Inc stock information, including NASDAQ: DSGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DSGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DSGN stock methods without spending real money on the virtual paper trading platform.